Last updated: January 30, 2026
Summary
Pemigatinib, marketed as PEMazyre, is a selective FGFR inhibitor developed by Incyte Corporation for treating cholangiocarcinoma and other FGFR-altered malignancies. As of 2023, it has gained accelerated approval by the U.S. Food and Drug Administration (FDA) for previously treated unresectable or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. This report provides a comprehensive overview of the latest clinical trials, current market landscape, competitive positioning, regulatory status, and future projections for pemigatinib.
Clinical Trials Landscape for Pemigatinib
Ongoing and Completed Trials
| Trial Phase |
Trial Identifier (NCT#) |
Purpose |
Status |
Sample Size |
Primary Endpoints |
| Phase 2 |
NCT02924376 |
Safety and Efficacy in Cholangiocarcinoma |
Completed (2021) |
146 |
ORR, DOR, PFS |
| Phase 3 |
NCT04198282 |
Confirmatory for FIGHT-302 (cholangiocarcinoma) |
Recruiting (2023) |
100-150 |
PFS, OS, ORR |
| Phase 1/2 |
NCT04557062 |
AML with FGFR mutations |
Ongoing |
50 |
Safety, Response Rate |
| Phase 2 |
NCT04520393 |
Solid tumors with FGFR alterations |
Recruiting |
60 |
ORR, Safety |
| Basket Trials |
NCT04697628 |
Various FGFR-altered solid tumors |
Ongoing |
Variable |
ORR, Safety |
Key Findings from Clinical Data
- Efficacy in Cholangiocarcinoma: The FIGHT-202 trial (Phase 2) demonstrated an ORR of approximately 35%, with median duration of response (DOR) around 7 months and median progression-free survival (PFS) near 7.2 months.
- Safety Profile: Common adverse events (AEs) include hyperphosphatemia (89%), alopecia, fatigue, and diarrhea. Serious AEs were infrequent.
- Regulatory Designations: Fast track, orphan drug, and breakthrough therapy designations granted by FDA and EMA.
Recent and Upcoming Clinical Milestones
| Date |
Milestone |
Details |
| Q2 2023 |
Data readout from FIGHT-302 (Phase 3) trial |
Expected to confirm PFS benefit |
| Q4 2024 |
Anticipated NDA submission for broader indications |
Pending clinical outcome data |
| 2025 |
Potential expansion into other FGFR-driven cancers |
Based on ongoing basket studies |
Market Analysis of Pemigatinib
Market Overview
| Parameter |
Details |
| Disease Focus |
Cholangiocarcinoma, urothelial carcinoma, bladder cancer, other FGFR-altered tumors |
| Estimated Global Market (2022) |
$250 million (mainly U.S., Europe, Asia) |
| CAGR (2022–2027) |
Approximately 15% (due to increasing FGFR mutation diagnostics and approvals) |
Key Market Drivers
- Unmet Medical Need: Limited targeted treatment options for FGFR-altered cholangiocarcinoma.
- Regulatory Approvals: Accelerated FDA approval enhances clinical adoption.
- Diagnostics Integration: Compulsory FGFR testing expands patient identification.
- Pipeline From Competitive FGFR Inhibitors: Erdafitinib (Jyseleca) and Futibatinib (Lytgobi) provide competition but with differing indications.
Competitive Landscape
| Drug |
Manufacturer |
Indications |
Approval Status |
Market Share (Est.) |
Key Differentiators |
| Pemigatinib (Pemazyre) |
Incyte |
Cholangiocarcinoma, urothelial carcinoma |
FDA/EMA approved; accelerated approval |
~60% |
First in class, specific for FGFR2 mutations |
| Futibatinib (Lytgobi) |
Taiho Pharma |
Multiple FGFR-driven tumors |
Approved (Japan, USA, others) |
~25% |
Irreversible binding, broader indication |
| Erdafitinib (Roflumia) |
Janssen |
Urothelial carcinoma |
FDA approved |
~10% |
Different tumor types, bladder focus |
| Others (e.g., Rogaratinib, TAS-120) |
Various |
Experimental/early stage |
Phase 1 or 2 |
Niche |
Emerging pipeline products |
Regulatory and Reimbursement Environment
- FDA: Fast-track, orphan drug, breakthrough designation support expedited review pathways.
- EMA: Conditional approval process; pending full approval.
- Reimbursement: Adjusted to clinical value; incorporated into guidelines for FGFR testing and treatment.
Market Projections (2023–2030)
| Projection Parameter |
2023 |
2025 |
2027 |
2030 |
| Global Market Value (USD) |
$300 M |
$600 M |
$1.1 B |
$2 B |
| CAGR (2023–2030) |
15% |
— |
— |
— |
| Number of Patients (Global) |
10,000 |
20,000 |
35,000 |
60,000 |
| Dominant Indications |
Cholangiocarcinoma |
Urothelial carcinoma |
Other FGFR-driven tumors |
Broad molecular indications |
Forecast Assumptions
- Increasing adoption of FGFR testing leading to earlier identification.
- Expanded indications through ongoing trials.
- Competitive differentiation maintained by efficacy and safety profiles.
- Pricing strategies aligned with niche molecular targeting.
Comparison with Similar Targeted Therapies
| Aspect |
Pemigatinib |
Futibatinib |
Erdafitinib |
| Approval Indications |
Cholangiocarcinoma, FGFR-mutant tumors |
Multiple FGFR-driven tumors |
Urothelial carcinoma |
| Mechanism of Action |
Reversible FGFR inhibitor |
Irreversible FGFR inhibitor |
Reversible FGFR inhibitor |
| Key Trial Data |
ORR 35%, DOR 7 months |
ORR 30%, DOR 8 months |
ORR 40%, DOR 6 months |
| Safety Profile |
Hyperphosphatemia, manageable |
Similar, slightly higher AEs |
Hyperphosphatemia, rash |
Regulatory and Policy Considerations
- Increased FDA focus on molecular diagnostics to match treatments.
- reimbursement policies include companion diagnostics coverage.
- Global access influenced by pricing, patent landscape, and manufacturing capacity.
Key Implications for Stakeholders
- Pharmaceutical Companies: Continued investment in FGFR inhibitor pipelines; potential for combination therapies.
- Investors: Significant upside potential contingent on trial outcomes and approval expansions.
- Clinicians: Need for integrative diagnostic infrastructure and education on FGFR-selective compounds.
- Patients: Enhanced access to targeted therapies with improved survival outcomes.
Key Takeaways
- Pemigatinib’s clinical pipeline is robust, with ongoing phase 3 trials potentially confirming its role in FGFR-driven tumors beyond cholangiocarcinoma.
- Market growth is driven primarily by increasing FGFR mutation testing, expanding indications, and regulatory support.
- The competitive landscape remains concentrated, with Pemigatinib holding a first-mover advantage for FGFR2-positive cholangiocarcinoma.
- Future outlook suggests a multi-billion-dollar market opportunity, provided clinical results sustain efficacy and safety profiles.
- Strategic considerations include partnership opportunities, pipeline expansion, and navigating regulatory pathways across regions.
FAQs
1. What are the main therapeutic indications for Pemigatinib?
Pemigatinib is chiefly approved for unresectable or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. Emerging data support its investigation in other FGFR-altered tumors, such as urothelial carcinoma and various solid tumors.
2. How does Pemigatinib compare to other FGFR inhibitors?
Pemigatinib is a reversible FGFR1-3 inhibitor with high selectivity, showing competitive efficacy in cholangiocarcinoma. It has demonstrated a favorable safety profile, with hyperphosphatemia as a class effect. It competes with irreversible inhibitors like Futibatinib, which may offer broader activity but with differing safety profiles.
3. What is the current regulatory status of Pemigatinib?
As of 2023, Pemigatinib has FDA accelerated approval in the U.S. and conditional approval in EMA countries for specific FGFR2-altered cholangiocarcinoma cases. Broader approval depends on confirmatory trial outcomes.
4. What are the key challenges in Pemigatinib’s market growth?
Challenges include managing adverse events, expanding indications, clinician awareness, diagnostic infrastructure for FGFR testing, and competition from other targeted therapies.
5. What is the projected global market for Pemigatinib by 2030?
The global market is projected to reach approximately $2 billion by 2030, driven by increased adoption, broader indications, and advancements in molecular diagnostics.
References
- FDA NDA Approval Document, Pemazyre (Pemigatinib), 2019
- Incyte Corporation Clinical Trial Data, 2022
- Market Research Future, FGFR Inhibitors Market Analysis, 2023
- European Medicines Agency Press Release, 2022
- ClinicalTrials.gov, Search for Pemigatinib Trials
Note: All projections are estimates based on current clinical trial results, regulatory trends, and market dynamics as of Q1 2023. Continued monitoring of trial outcomes and regulatory decisions is essential for real-time strategic planning.
